Back

A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern

Wagner, T. R.; Schnepf, D.; Beer, J.; Klingel, K.; Ruetalo, N.; Kaiser, P. D.; Junker, D.; Sauter, M.; Traenkle, B.; Frecot, D. I.; Becker, M.; Schneiderhan-Marra, N.; Ohnemus, A.; Schwemmle, M.; Schindler, M.; Rothbauer, U.

2021-08-09 biochemistry
10.1101/2021.08.08.455562 bioRxiv
Show abstract

The ongoing COVID-19 pandemic and the frequent emergence of new SARS-CoV-2 variants of concern (VOCs), requires continued development of fast and effective therapeutics. Recently, we identified high-affinity neutralizing nanobodies (Nb) specific for the receptor-binding domain (RBD) of SARS-CoV-2, which are now being used as biparatopic Nbs (bipNbs) to investigate their potential as future drug candidates. Following detailed in vitro characterization, we chose NM1267 as the most promising candidate showing high affinity binding to several recently described SARS-CoV-2 VOCs and strong neutralizing capacity against a patient isolate of B.1.351 (Beta). To assess if bipNb NM1267 confers protection against SARS-CoV-2 infection in vivo, human ACE2 transgenic mice were treated by intranasal route before infection with a lethal dose of SARS-CoV-2. NM1267-treated mice showed significantly reduced disease progression, increased survival rates and secreted less infectious virus via their nostrils. Histopathological analyses and in situ hybridization further revealed a drastically reduced viral load and inflammatory response in lungs of NM1267-treated mice. These data suggest, that bipNb NM1267 is a broadly active and easily applicable drug candidate against a variety of emerging SARS-CoV-2 VOCs.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Antiviral Research
○ 50 papers in training set
Top 0.1%
26.0%
Similar papers in this journal
2
Viruses
○ 332 papers in training set
Top 0.9%
5.4%
Similar papers in this journal
3
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.1%
5.1%
Similar papers in this journal
4
iScience
○ 1154 papers in training set
Top 3%
5.1%
Similar papers in this journal
5
Cell Reports
○ 1498 papers in training set
Top 8%
4.8%
Similar papers in this journal
6
Life Science Alliance
● 285 papers in training set
Top 0.9%
4.0%
50% of probability mass above
7
eLife
● 5828 papers in training set
Top 37%
3.2%
8
EMBO Reports
○ 263 papers in training set
Top 2%
3.2%
9
The EMBO Journal
○ 309 papers in training set
Top 2%
3.2%
10
Cell Reports Medicine
○ 153 papers in training set
Top 1%
3.0%
11
PLOS Pathogens
● 820 papers in training set
Top 5%
2.6%
12
Scientific Reports
○ 3612 papers in training set
Top 54%
1.7%
13
Frontiers in Virology
○ 15 papers in training set
Top 0.1%
1.7%
14
Cellular and Molecular Life Sciences
○ 96 papers in training set
Top 0.9%
1.5%
15
Emerging Microbes & Infections
○ 74 papers in training set
Top 0.8%
1.3%
16
International Journal of Molecular Sciences
○ 494 papers in training set
Top 12%
1.1%
17
mAbs
○ 32 papers in training set
Top 0.3%
1.1%
18
Cells
○ 249 papers in training set
Top 5%
1.1%
19
Nature Communications
○ 5641 papers in training set
Top 51%
1.1%
20
Virology
○ 61 papers in training set
Top 1.0%
1.1%
21
Cell
○ 431 papers in training set
Top 8%
1.1%
22
Cell Reports Methods
○ 165 papers in training set
Top 3%
1.0%
23
Heliyon
○ 152 papers in training set
Top 7%
1.0%
24
Journal of Neurochemistry
○ 53 papers in training set
Top 1%
0.9%
25
Biochemical Journal
● 91 papers in training set
Top 2%
0.8%
26
Communications Biology
○ 993 papers in training set
Top 31%
0.8%
27
Frontiers in Immunology
○ 638 papers in training set
Top 10%
0.8%
28
Vaccines
○ 198 papers in training set
Top 4%
0.8%
29
Nucleic Acids Research
◐ 1281 papers in training set
Top 15%
0.6%
30
Journal of Virological Methods
○ 37 papers in training set
Top 0.5%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.